In Depth 27 Jun 2024
CRISPR-Cas13: how does the technology compare to its famous Cas9 cousin?
Discover more about CRISPR-Cas13, including how it differs from CRISPR-Cas9 and what the technology can be used for.
- Latest Posts
In Depth 27 Jun 2024
The 2024 drug approval list: Eight new treatments you should know about
In this article, we take a look at eight much-anticipated drugs that have been approved by regulators so far this year.
In Depth 26 Jun 2024
Biotech megadeals: Exploring the surge in $100M+ deals
Biotech and healtcare contributed to more than one out of three megadeals in 2024, find out the reasons behind it.
Best in Biotech 25 Jun 2024
Spotlight on Georgia’s biotech industry: Seven companies to know about in 2024
Delve into the biotech landscape of the state of Georgia and discover seven companies leading the charge in the industry.
In Depth 24 Jun 2024
Troublesome acquisitions: when biotech M&A goes wrong
Dive deeper into the world of M&A, as we take a look at some of the most prominent failed acquisitions of the last decade.
Best in Biotech 21 Jun 2024
Five biotechnology colleges in India cultivating future leaders
Take a closer look at five biotechnology colleges in India offering courses that can lead to numerous opportunities for students.
ADVERTISEMENT
ADVERTISEMENT
Podcast 21 Jun 2024
How ADCs can deliver death cap mushroom toxins to treat cancer
Listen to our conversation with Heidelberg Pharma about its lead amanitin-based ADC product candidate, HDP-101.
Best in Biotech 20 Jun 2024
CRISPR technology’s next wave: Eight companies to watch in 2024
Driven by CASGEVY’s success, the CRISPR field is experiencing substantial growth with a new wave of companies.
In Depth 19 Jun 2024
MASH candidates make a splash after first drug approval
The first drug to treat MASH, a potentially life-threatening liver disease, was approved this year. More recent advancements bring hope to patients.
Best in Biotech 18 Jun 2024
5 companies spearheading the emerging biotech scene in the Balkans
Take a look at five biotech companies in the Balkans spearheading the emerging biotech scene in the region.
Overcoming obstacles as advanced therapies continue to evolve in Europe
Discover strategies to overcome the challenges in advanced therapy development in Europe’s evolving biopharmaceutical landscape.
In Depth 17 Jun 2024
Moving with the times: biopharma royalty deals on the rise
A spate of royalty deals are changing the way certain biotechs press ahead. This trend seems to be an alternative to traditional biopharma fundraising.
ADVERTISEMENT
